The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

被引:13
|
作者
Moon H. [1 ]
Noh W.C. [2 ]
Kim H.-A. [2 ]
Kim E.-K. [2 ]
Park K.W. [3 ]
Lee S.S. [4 ,5 ]
Choi J.H. [1 ]
Han K.W. [1 ]
Byun B.H. [1 ]
Lim I. [1 ]
Kim B.I. [1 ]
Choi C.W. [1 ]
Lim S.M. [1 ]
机构
[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75, Nowon-ro, Nowon-gu, Seoul
[2] Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[3] Department of Radiology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[4] National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[5] Department of Pathology, Korea Cancer Center Hospital, Seoul
关键词
Breast cancer; Dual phase; Estrogen receptor; Human epidermal growth factor receptor 2; Positron emission tomography; Retention index;
D O I
10.1007/s13139-016-0412-2
中图分类号
学科分类号
摘要
Purpose: This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods: A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen. Results: RImean was significantly higher in ER (−) (median, 16.2; IQR, 10.8–21.0) or HER-2 (+) (median, 16.1; IQR, 10.7–21.6) tumors than in ER (+) tumors (median, 9.9; IQR, 5.5–15.3) or HER-2 (−) tumors (median, 10.5; IQR, 5.5–16.1). However, there were no significant differences of SUVmax or RImax according to the ER or HER-2 status. There were no significant differences of any PET parameters between PR (+) and PR (−) tumors. Based off ROC curve analyses, RImean predicted the ER (+) tumors (AUC, 0.699; p = 0.006), and HER-2 (+) tumors (AUC, 0.674; p = 0.022), but not the PR (+) tumors. However, neither SUVmax nor RImax predicted ER (+), PR (+), or HER-2 (+) tumors. Conclusions: Retention index of SUVmean can reflect the ER and HER-2 status of breast cancers. Higher retention index of SUVmean might associate with lower ER expression and higher HER-2 expression. © 2016, Korean Society of Nuclear Medicine.
引用
收藏
页码:246 / 254
页数:8
相关论文
共 50 条
  • [31] Reliability of Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Expression on Breast Cancer Cells Stored in Cellprep® Vials
    Ryu, Ayumi
    Ashimura, Jyun-ichi
    Nakayama, Takahiro
    Tamaki, Yasuhiro
    Nakatsuka, Shin-ichi
    Tomita, Yasuhiko
    ACTA CYTOLOGICA, 2018, 62 (5-6) : 360 - 370
  • [32] Comparisons between core needle biopsy and definite surgery in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expressions in breast carcinoma
    Hsiao, Y.
    Chen, J.
    Kuo, S.
    Chen, D.
    Chou, M.
    Chen, S.
    EJC SUPPLEMENTS, 2010, 8 (03): : 229 - 229
  • [33] 18F-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors
    Filizoglu, Nuh
    Ozguven, Salih
    Erdil, Tanju Yusuf
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (09) : E605 - E606
  • [34] Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma
    Kai-Hsiung Ko
    Hsian-He Hsu
    Tsai-Wang Huang
    Hong-Wei Gao
    Daniel H. Y. Shen
    Wei-Chou Chang
    Yi-Chih Hsu
    Tsun-Hou Chang
    Chi-Ming Chu
    Ching-Liang Ho
    Hung Chang
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 1889 - 1897
  • [35] CORRELATION BETWEEN STEROID-RECEPTORS (ESTROGEN-RECEPTOR AND PROGESTERONE-RECEPTOR) AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN MAMMARY BREAST-CANCER
    EPPENBERGER, U
    FABBRO, D
    WYSS, R
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1986, 24 (10): : 752 - 752
  • [36] Characterization of Estrogen Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Li, Ming
    Lv, Hong
    Shui, Ruohong
    Lu, Hongfen
    Yang, Wentao
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 151 - 151
  • [37] Characterization of Estrogen Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Li, Ming
    Lv, Hong
    Shui, Ruohong
    Lu, Hongfen
    Yang, Wentao
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 151 - 151
  • [38] INVERSE RELATIONSHIP BETWEEN ESTROGEN-RECEPTOR AND EPIDERMAL GROWTH-FACTOR RECEPTOR GENE-EXPRESSION IN HUMAN-BREAST CANCER-CELLS
    SUTHERLAND, RL
    LEE, CSL
    ALEXANDER, IE
    HALL, RE
    SHINE, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 247 - 247
  • [39] AMPHIREGULIN, EPIDERMAL GROWTH-FACTOR RECEPTOR, AND ESTROGEN-RECEPTOR EXPRESSION IN HUMAN PRIMARY BREAST-CANCER
    LEJEUNE, S
    LEEK, R
    HORAK, E
    PLOWMAN, G
    GREENALL, M
    HARRIS, AL
    CANCER RESEARCH, 1993, 53 (15) : 3597 - 3602
  • [40] A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
    Aurilio, Gaetano
    Disalvatore, Davide
    Pruneri, Giancarlo
    Bagnardi, Vincenzo
    Viale, Giuseppe
    Curigliano, Giuseppe
    Adamoli, Laura
    Munzone, Elisabetta
    Sciandivasci, Angela
    De Vita, Fernando
    Goldhirsch, Aron
    Nole, Franco
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 277 - 289